2Ramos J, Villa J, Ruiz A, et al. (2004) UV dose determines key characteristics of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 13, 2006–2011.
3Acharya A, Das I, Chandhok D, et al. (2010) Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev 3, 23–34.
4Sander CS, Hamm F, Elsner P, et al. (2003) Oxidative stress in malignant melanoma and non-melanoma skin cancer. Br J Dermatol 148, 913–922.
5Sporn MB, Dunlop NM, Newton DL, et al. (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35, 1332–1338.
6Tapsell LC, Hemphill I, Cobiac L, et al. (2006) Health benefits of herbs and spices: the past, the present, the future. Med J Aust 185, S4–24.
7Wikipedia TFE (2011) .
8Zachariah TJ Chemistry of cardamom. In Cardamom, The Genus Elettaria [Ravindran PM and Madhusoodanan KJ, editors]. London: Taylor and Francis.
9Acharya A, Das I, Singh S, et al. (2010) Chemopreventive properties of indole-3-carbinol, diindolylmethane and other constituents of cardamom against carcinogenesis. Recent Pat Food Nutr Agric 2, 166–177.
10Huang YB, Fang JY, Hung CH, et al. (1999) Cyclic monoterpene extract from cardamom oil as a skin permeation enhancer for indomethacin: in vitro and in vivo studies. Biol Pharm Bull 22, 642–646.
11Bhattacharjee S, Rana T & Sengupta A (2007) Inhibition of lipid peroxidation and enhancement of GST activity by cardamom and cinnamon during chemically induced colon carcinogenesis in Swiss albino mice. Asian Pac J Cancer Prev 8, 578–582.
12Das I & Saha T (2009) Effect of garlic on lipid peroxidation and antioxidation enzymes in DMBA-induced skin carcinoma. Nutrition 25, 459–471.
13Ando S, Kon K, Aino K, et al. (1990) Increased levels of lipid peroxides in aged rat brain as revealed by direct assay of peroxide values. Neurosci Lett 113, 199–204.
14Habig WH, Pabst MJ & Jakoby WB (1974) Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249, 7130–7139.
15Paglia DE & Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70, 158–169.
16Luck H (1963) A spectrophotometric method for the measurement of catalase. Meth Enzymatic Anal 27, 885–895.
17Marklund S & Marklund G (1974) Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47, 469–474.
18Sedlak J & Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 25, 192–205.
19Carberg I & Mannervick B (1985) Glutathione reductase. In Methods in Enzymology [Fleisher S and Packer L, editors]. New York, NY: Academic Press.
20Das I, Das S & Saha T (2009) Saffron suppresses oxidative stress in DMBA-induced skin carcinoma: a histopathological study. Acta Histochem 26, 26.
21Cho HY, Reddy SP, Debiase A, et al. (2005) Gene expression profiling of NRF2-mediated protection against oxidative injury. Free Radic Biol Med 38, 325–343.
22Kensler TW & Wakabayashi N (2009) Nrf2: friend or foe for chemoprevention? Carcinogenesis 30, 30.
23Motohashi H & Yamamoto M (2004) Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 10, 549–557.
24Baud V & Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8, 33–40.
25Zandi E, Rothwarf DM, Delhase M, et al. (1997) The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91, 243–252.
26Sochanowicz B, Szumiel I & Gradzka I (1999) Nuclear translocation of the p65 subunit of NF-kappaB in L5178Y sublines differing in antioxidant defense. Radiat Environ Biophys 38, 125–131.
27Miglietta A, Toselli M, Ravarino N, et al. (2010) COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers. Expert Opin Ther Targets 14, 655–664.
28An KP, Athar M, Tang X, et al. (2002) Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 76, 73–80.
29Surh YJ (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3, 768–780.
30Katiyar SK & Mukhtar H (2001) Green tea polyphenol ( − )-epigallocatechin-3-gallate treatment to mouse skin prevents UVB-induced infiltration of leukocytes, depletion of antigen-presenting cells, and oxidative stress. J Leukoc Biol 69, 719–726.
31Wei H, Zhang X, Wang Y, et al. (2002) Inhibition of ultraviolet light-induced oxidative events in the skin and internal organs of hairless mice by isoflavone genistein. Cancer Lett 185, 21–29.
32Wang Y, Zhang X, Lebwohl M, et al. (1998) Inhibition of ultraviolet B (UVB)-induced c-fos and c-jun expression in vivo by a tyrosine kinase inhibitor genistein. Carcinogenesis 19, 649–654.
33Afaq F, Adhami VM & Ahmad N (2003) Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol Appl Pharmacol 186, 28–37.
34Adhami VM, Afaq F & Ahmad N (2003) Suppression of ultraviolet B exposure-mediated activation of NF-kappaB in normal human keratinocytes by resveratrol. Neoplasia 5, 74–82.
35Katiyar SK, Korman NJ, Mukhtar H, et al. (1997) Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 89, 556–566.
36Cho JW, Park K, Kweon GR, et al. (2005) Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets. Exp Mol Med 37, 186–192.
37Kim JK, Kim Y, Na KM, et al. (2007) -Gingerol prevents UVB-induced ROS production and COX-2 expression in vitro and in vivo. Free Radic Res 41, 603–614.
38Fazekas Z, Gao D, Saladi RN, et al. (2003) Protective effects of lycopene against ultraviolet B-induced photodamage. Nutr Cancer 47, 181–187.
39Kowalczyk MC, Kowalczyk P, Tolstykh O, et al. (2010) Synergistic effects of combined phytochemicals and skin cancer prevention in SENCAR mice. Cancer Prev Res 3, 170–178.
40Bowden GT, Schneider B, Domann R, et al. (1994) Oncogene activation and tumor suppressor gene inactivation during multistage mouse skin carcinogenesis. Cancer Res 54, 1882s–1885s.
41Kapadia GJ, Azuine MA, Sridhar R, et al. (2003) Chemoprevention of DMBA-induced UV-B promoted, NOR-1-induced TPA promoted skin carcinogenesis, and DEN-induced phenobarbital promoted liver tumors in mice by extract of beetroot. Pharmacol Res 47, 141–148.
42Kim MO, Kim SH, Shin MJ, et al. (2007) DMBA/TPA-induced tumor formation is aggravated in human papillomavirus type 16 E6/E7 transgenic mouse skin. Oncol Res 16, 325–332.
43Schneider BL, Bowden GT, Sutter C, et al. (1993) 7,12-Dimethylbenz[a]anthracene-induced mouse keratinocyte malignant transformation independent of Harvey ras activation. J Invest Dermatol 101, 595–599.
44Bhattacharyya SS, Paul S, Mandal SK, et al. (2009) A synthetic coumarin (4-methyl-7 hydroxy coumarin) has anti-cancer potentials against DMBA-induced skin cancer in mice. Eur J Pharmacol 614, 128–136.
45Chaudhary SC, Alam MS, Siddiqui MS, et al. (2009) Chemopreventive effect of farnesol on DMBA/TPA-induced skin tumorigenesis: involvement of inflammation. Ras-ERK pathway and apoptosis. Life Sci 85, 196–205.
46Bartsch H & Nair J (2005) Accumulation of lipid peroxidation-derived DNA lesions: potential lead markers for chemoprevention of inflammation-driven malignancies. Mutat Res 591, 34–44.
47Hayes JD & McMahon M (2009) NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34, 176–188.
48Wang R, An J, Ji F, et al. (2008) Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 373, 151–154.
49Ulivi V, Giannoni P, Gentili C, et al. (2008) p38/NF-kB-dependent expression of COX-2 during differentiation and inflammatory response of chondrocytes. J Cell Biochem 104, 1393–1406.
50Kim HJ, Hawke N & Baldwin AS (2006) NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 13, 738–747.
51Perkins ND & Gilmore TD (2006) Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ 13, 759–772.
52Kobielak A & Fuchs E (2006) Links between alpha-catenin, NF-kappaB, and squamous cell carcinoma in skin. Proc Natl Acad Sci U S A 103, 2322–2327.
53Huang S, DeGuzman A, Bucana CD, et al. (2000) Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity. Cytokines Cell Mol Ther 6, 9–17.
54Payne AS & Cornelius LA (2002) The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 118, 915–922.
55Richmond A (2002) Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2, 664–674.
56Li JJ, Rhim JS, Schlegel R, et al. (1998) Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene 16, 2711–2721.
57Dajee M, Lazarov M, Zhang JY, et al. (2003) NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421, 639–643.
58Saleem M, Afaq F, Adhami VM, et al. (2004) Lupeol modulates NF-kappaB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice. Oncogene 23, 5203–5214.
59Arora N, Bansal MP & Koul A (2011) Azadirachta indica exerts chemopreventive action against murine skin cancer: studies on histopathological, ultrastructural changes and modulation of NF-kappaB, AP-1, and STAT1. Oncol Res 19, 179–191.